US04962H5063 - Common Stock
ATOSSA THERAPEUTICS INC
NASDAQ:ATOS (4/29/2024, 3:43:51 PM)
After market: 1.54 +0.01 (+0.65%)1.53
0 (0%)
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 9 full-time employees. The company went IPO on 2012-11-08. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. The company is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.
ATOSSA THERAPEUTICS INC
107 Spring St
Seattle WASHINGTON 98104
P: 12065880256
CEO: Steven C. Quay
Employees: 9
Website: https://atossatherapeutics.com/
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research...
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare...
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive...
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and...
ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Here you can normally see the latest stock twits on ATOS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: